MetLife Investment Management
KROS icon

MetLife Investment Management’s Keros Therapeutics KROS Stock Holding History

MetLife Investment Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$178K Hold
16,682
– – ﹤0.01% 2481
2026
Q1 		$184K Hold
16,682
– – ﹤0.01% 2271
2025
Q4 		$340K Sell
16,682
-3,067
-16% -$53.8K ﹤0.01% 1982
2025
Q3 		$312K Hold
19,749
– – ﹤0.01% 2058
2025
Q2 		$264K Buy
19,749
+1,651
+9% +$22.3K ﹤0.01% 2031
2025
Q1 		$184K Hold
18,098
– – ﹤0.01% 2243
2024
Q4 		$286K Buy
18,098
+1,027
+6% +$53.4K ﹤0.01% 2102
2024
Q3 		$991K Hold
17,071
– – 0.01% 1392
2024
Q2 		$780K Buy
17,071
+3,928
+30% +$211K ﹤0.01% 1483
2024
Q1 		$870K Buy
13,143
+1,258
+11% +$74.6K 0.01% 1377
2023
Q4 		$473K Hold
11,885
– – ﹤0.01% 1720
2023
Q3 		$379K Hold
11,885
– – ﹤0.01% 1799
2023
Q2 		$478K Buy
11,885
+1,788
+18% +$78.4K ﹤0.01% 1718
2023
Q1 		$431K Hold
10,097
– – ﹤0.01% 1733
2022
Q4 		$485K Buy
10,097
+1,642
+19% +$76.7K ﹤0.01% 1663
2022
Q3 		$318K Hold
8,455
– – ﹤0.01% 1970
2022
Q2 		$234K Hold
8,455
– – ﹤0.01% 2206
2022
Q1 		$460K Buy
8,455
+2,999
+55% +$154K ﹤0.01% 1823
2021
Q4 		$319K Hold
5,456
– – ﹤0.01% 1776
2021
Q3 		$216K Hold
5,456
– – ﹤0.01% 2043
2021
Q2 		$232K Hold
5,456
– – ﹤0.01% 2065
2021
Q1 		$336K Hold
5,456
– – ﹤0.01% 1748
2020
Q4 		$385K Buy
5,456
+1,646
+43% +$104K ﹤0.01% 1607
2020
Q3 		$147K Hold
3,810
– – ﹤0.01% 2036
2020
Q2 		$143K Buy
+3,810
New +$117K ﹤0.01% 2079

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

MetLife Investment Management's KROS Position: Q2 2026 in Review

MetLife Investment Management held its Keros Therapeutics (KROS) position steady in Q2 2026 at 16,682 shares worth $178K. The position accounts for ﹤0.01% of the portfolio, ranked #2481.

MetLife Investment Management first reported a position in KROS in Q2 2020 and has held it in 25 quarters since. The position peaked at $991K in Q3 2024. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • MetLife Investment Management held 16,682 shares of Keros Therapeutics worth $178K as of Q2 2026.
  • MetLife Investment Management left its Keros Therapeutics share count unchanged in Q2 2026.
  • Keros Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2481 holding.
  • MetLife Investment Management first reported a position in Keros Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • MetLife Investment Management's Keros Therapeutics position peaked at $991K in Q3 2024.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.